Using our three stage approach enables you to determine an accurate and transparent value for your early clinical stage compound:
Stage 1 - Review of Target Product Profile & Clinical Development Plan.
A review of your TPP & CDP identifies target indication, time and risks associated with your program.
Stage 2 - Cost & Revenue modeling High-level cost estimates are identified to determine the costs related to the clinical studies outlined in your CDP. Revenue estimates are modeled using standard techniques.
Stage 3 - Valuation In this final stage a risk adjusted approach is used to ultimately estimate a fair value for your your early clinical stage compound. The flexible models we use also allow for taking into account payment of milestones or cost-sharing.
In addition we can also assist you with compiling a comprehensive Product Development Plan outlining the manufacturing/CMC, preclinical, clinical and regulatory strategy and tactics.